apoddc's profile picture. We’ll be hosting Clinical Trial Design webinars in 2023! Follow us to be kept up to date. 📊🧑🏻‍💻

APODDC

@apoddc

We’ll be hosting Clinical Trial Design webinars in 2023! Follow us to be kept up to date. 📊🧑🏻‍💻

APODDC reposted

📢 #Happy to share w/ #LCSM community! After 3+ years of work, we are pleased to share our #cost_effectiveness modelling for #lungcancer 🫁 #screening 🏥📸 in both #high-risk populations determined by both #smoking & #non-smoking risk factors e.g. family history for an entire…

herbloong's tweet image. 📢 #Happy to share w/ #LCSM community! After 3+ years of work, we are pleased to share our #cost_effectiveness modelling for #lungcancer 🫁 #screening 🏥📸 in both #high-risk populations determined by both #smoking & #non-smoking risk factors e.g. family history for an entire…

APODDC reposted

Safety of tarlatamab with 6-8h outpatient vs 48-h inpatient monitoring during C1: DeLLphi-300 ph1 substudy in @ESMO_Open. Outpatient monitoring feasible, same CRS rate, most managed w/o hospitalization/ER visit. Anticipate&monitor AEs in educated pts is🔑. esmoopen.com/article/S2059-…

ESMO_Open's tweet image. Safety of tarlatamab with 6-8h outpatient vs 48-h inpatient monitoring during C1: DeLLphi-300 ph1 substudy in @ESMO_Open. Outpatient monitoring feasible, same CRS rate, most managed w/o hospitalization/ER visit. Anticipate&monitor AEs in educated pts is🔑. esmoopen.com/article/S2059-…

APODDC reposted

Newly published ESMO recommendations provide roadmap for the implementation of molecular tumour boards in clinical practice. Discover the key focus areas to optimise #PrecisionOncology Read via #ESMODailyReporter: ow.ly/mexL50VvtUM @BenWestphalen @Annals_Oncology

myESMO's tweet image. Newly published ESMO recommendations provide roadmap for the implementation of molecular tumour boards in clinical practice.
Discover the key focus areas to optimise #PrecisionOncology
Read via #ESMODailyReporter: ow.ly/mexL50VvtUM
  
@BenWestphalen @Annals_Oncology

APODDC reposted

Wonderful crew of @myESMO #ESMORarecancer25 #YOCasesDiscussion session! Definitely not-so-young oncologists including #myself are also welcome. Great cases discussed and thanks everyone for contributing to lively discussions. @pawel_sobczuk @DrLizConnolly @Robertasanfili

herbloong's tweet image. Wonderful crew of @myESMO #ESMORarecancer25 #YOCasesDiscussion session! Definitely not-so-young oncologists including #myself are also welcome. 

Great cases discussed and thanks everyone for contributing to lively discussions. 

@pawel_sobczuk @DrLizConnolly @Robertasanfili…

APODDC reposted

It's pleasure coauthoring this @Cancer_Cell commentary with 2 talented drug development fellows #gregoire marret and #mercedes herrera @pmcancercentre - "Turning the Kaleidoscope: Innovations shaping the future of clinical trials design" authors.elsevier.com/a/1kljp5TA51lC…

lillian_siu's tweet image. It's pleasure coauthoring this @Cancer_Cell commentary with 2 talented drug development fellows #gregoire marret and #mercedes herrera @pmcancercentre - "Turning the Kaleidoscope: Innovations shaping the future of clinical trials design"
authors.elsevier.com/a/1kljp5TA51lC…

APODDC reposted

🔥 @JCO_ASCO 🆙 ✅LIBRETTO-001 final: Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer 🎯mOS 47.6 (pretreated pts), not reached (treatment-naïve) 👥 @GautschiOliver #LCSM @OncoAlert

Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer #NSCLC 🫁 : Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial buff.ly/YlqitQJ This phase I/II study evaluating selpercatinib in RET fusion-positive non–small…

OncoAlert's tweet image. Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer #NSCLC 🫁 : Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial 

buff.ly/YlqitQJ

This phase I/II study evaluating selpercatinib in RET fusion-positive non–small…


APODDC reposted

Delighted to share our review paper on ADCs in NSCLC with AGA is out! Very timely given the anticipated data readouts this year. Such an honour to be a part of this awesome team, special thanks to @g_mountzios and @JordiRemon for leading this 🙌🏻

Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted #NSCLC❓ 💡Just out in @myESMO #CancerTreatmentReviews a comprehensive overview on current landscape, challenges and perspectives Grateful to work with a global amazing team, including @stephanieplsaw

g_mountzios's tweet image. Biomarker-selected or  biomarker-agnostic ADCs for oncogene-addicted #NSCLC❓

💡Just out  in  @myESMO  #CancerTreatmentReviews  a comprehensive overview on current landscape, challenges and perspectives

Grateful to work with a global amazing team, including @stephanieplsaw…
g_mountzios's tweet image. Biomarker-selected or  biomarker-agnostic ADCs for oncogene-addicted #NSCLC❓

💡Just out  in  @myESMO  #CancerTreatmentReviews  a comprehensive overview on current landscape, challenges and perspectives

Grateful to work with a global amazing team, including @stephanieplsaw…
g_mountzios's tweet image. Biomarker-selected or  biomarker-agnostic ADCs for oncogene-addicted #NSCLC❓

💡Just out  in  @myESMO  #CancerTreatmentReviews  a comprehensive overview on current landscape, challenges and perspectives

Grateful to work with a global amazing team, including @stephanieplsaw…
g_mountzios's tweet image. Biomarker-selected or  biomarker-agnostic ADCs for oncogene-addicted #NSCLC❓

💡Just out  in  @myESMO  #CancerTreatmentReviews  a comprehensive overview on current landscape, challenges and perspectives

Grateful to work with a global amazing team, including @stephanieplsaw…


APODDC reposted

It's ok at #CTOS2024 to drag me to your poster to pitch your science for Clinical Cancer Research, it the most inspiring thing i get to do!!


APODDC reposted

Phase 2 Study: Trametinib Treatment of Epithelioid Hemangioendothelioma. bit.ly/40pDRBc

CCR_AACR's tweet image. Phase 2 Study: Trametinib Treatment of Epithelioid Hemangioendothelioma. bit.ly/40pDRBc

APODDC reposted

Thanks @drkiwicj @drkiwikate @anmwongNZ @cameroncologist #DaisyMak (who needs to get on Twitter! 😆) & all my other 🇳🇿 #oncology friends @NzsOncology for your invitation & hospitality. Amazing talks & discussions throughout the conference. Perfect forum to build collaborations.…

What a privilege to have an academic of the quality of @herbloong speaking at @NzsOncology on precision oncology. Kia Ora Herbert!

drkiwicj's tweet image. What a privilege to have an academic of the quality of @herbloong speaking at @NzsOncology on precision oncology. Kia Ora Herbert!


APODDC reposted

Thank you superstar @herbloong for being a keynote speaker @NzsOncology Timely discussions on accessibility/ cost savings for #PrecisionOncology Need personalise a model for 🇳🇿 too! @apoddc @TeWhatuOra @cancer_agency

anmwongNZ's tweet image. Thank you superstar @herbloong for being a keynote speaker @NzsOncology 

Timely discussions on accessibility/ cost savings for #PrecisionOncology 

Need personalise a model for 🇳🇿 too!

@apoddc @TeWhatuOra @cancer_agency
anmwongNZ's tweet image. Thank you superstar @herbloong for being a keynote speaker @NzsOncology 

Timely discussions on accessibility/ cost savings for #PrecisionOncology 

Need personalise a model for 🇳🇿 too!

@apoddc @TeWhatuOra @cancer_agency

APODDC reposted

Thank you @jeanyvesblay for your excellent talk at the @cddf_eu - @EORTC workshop #RareCancers You last slides summarized it so well

Winette_vdGraaf's tweet image. Thank you @jeanyvesblay for your excellent talk at the @cddf_eu - @EORTC  workshop #RareCancers

You last slides summarized  it so well
Winette_vdGraaf's tweet image. Thank you @jeanyvesblay for your excellent talk at the @cddf_eu - @EORTC  workshop #RareCancers

You last slides summarized  it so well

APODDC reposted

Thanks @drdgoldstein for coming all the way from 🇮🇱 to 🇭🇰 to share insights and experiences in #pharmacoeconomics. Organised by #ProfVivianLee and colleagues of @cuhkpharmacy Very engaged workshop together with stakeholders from #academia, #industry, #patientsrepresentatives and…

herbloong's tweet image. Thanks @drdgoldstein for coming all the way from 🇮🇱 to 🇭🇰 to share insights and experiences in #pharmacoeconomics. Organised by #ProfVivianLee and colleagues of @cuhkpharmacy  Very engaged workshop together with stakeholders from #academia, #industry, #patientsrepresentatives and…
herbloong's tweet image. Thanks @drdgoldstein for coming all the way from 🇮🇱 to 🇭🇰 to share insights and experiences in #pharmacoeconomics. Organised by #ProfVivianLee and colleagues of @cuhkpharmacy  Very engaged workshop together with stakeholders from #academia, #industry, #patientsrepresentatives and…
herbloong's tweet image. Thanks @drdgoldstein for coming all the way from 🇮🇱 to 🇭🇰 to share insights and experiences in #pharmacoeconomics. Organised by #ProfVivianLee and colleagues of @cuhkpharmacy  Very engaged workshop together with stakeholders from #academia, #industry, #patientsrepresentatives and…
herbloong's tweet image. Thanks @drdgoldstein for coming all the way from 🇮🇱 to 🇭🇰 to share insights and experiences in #pharmacoeconomics. Organised by #ProfVivianLee and colleagues of @cuhkpharmacy  Very engaged workshop together with stakeholders from #academia, #industry, #patientsrepresentatives and…

📢Announcement: Join us at our 1st #APODDCForum2024 where we discuss about the Regulatory Harmonisation for Oncology Clinical Trials & Therapeutics Registration in the APAC Region📷 Sign up now via lnkd.in/gDPsHNib!📧 More details on our LinkedIn Page!

apoddc's tweet image. 📢Announcement:  Join us at our 1st #APODDCForum2024 where we discuss about the Regulatory Harmonisation for Oncology Clinical Trials & Therapeutics Registration in the APAC Region📷 Sign up now via lnkd.in/gDPsHNib!📧 More details on our LinkedIn Page!

APODDC reposted

📢 T-28 days to our 6th @CUHKMedicine #CUHKSarcoma Masterclass in #hongkong 🇭🇰! We are looking forward to welcoming #international and #local faculties to our annual event. Congrats to 8 overseas attendees who have been #awarded #travelgrants to #present and #attend this year's…

herbloong's tweet image. 📢 T-28 days to our 6th @CUHKMedicine #CUHKSarcoma Masterclass in #hongkong 🇭🇰! We are looking forward to welcoming #international and #local faculties to our annual event. Congrats to 8 overseas attendees who have been #awarded #travelgrants to #present and #attend this year's…

APODDC reposted

Truly honored to have been invited to speak on EGFR-mut NSCLC at the National Cancer Center in Singapore by Daniel Tan and his incredible team. Grateful for the opportunity to share insights and collaborate on such an important topic @danieltanmd @SingHealthSG @pankajpanda86

APassaroMD's tweet image. Truly honored to have been invited to speak on EGFR-mut NSCLC at the National Cancer Center in Singapore by Daniel Tan and his incredible team. Grateful for the opportunity to share insights and collaborate on such an important topic @danieltanmd @SingHealthSG @pankajpanda86…

APODDC reposted

Congrats @jeanyvesblay & colleagues of #FrenchSarcomaGroup for completing study of #6vs3years of #adjuvant #imatinib 💊i n pts w/ #highrisk #GISTs. Presented at @myESMO @AACR #virtualplenary over last #2days with #specific discussions from #APAC #discussants as well!…

herbloong's tweet image. Congrats @jeanyvesblay & colleagues of #FrenchSarcomaGroup for completing study of #6vs3years of #adjuvant #imatinib 💊i n pts w/ #highrisk #GISTs. Presented at @myESMO @AACR  #virtualplenary over last #2days with #specific discussions from #APAC #discussants as well!…
herbloong's tweet image. Congrats @jeanyvesblay & colleagues of #FrenchSarcomaGroup for completing study of #6vs3years of #adjuvant #imatinib 💊i n pts w/ #highrisk #GISTs. Presented at @myESMO @AACR  #virtualplenary over last #2days with #specific discussions from #APAC #discussants as well!…
herbloong's tweet image. Congrats @jeanyvesblay & colleagues of #FrenchSarcomaGroup for completing study of #6vs3years of #adjuvant #imatinib 💊i n pts w/ #highrisk #GISTs. Presented at @myESMO @AACR  #virtualplenary over last #2days with #specific discussions from #APAC #discussants as well!…
herbloong's tweet image. Congrats @jeanyvesblay & colleagues of #FrenchSarcomaGroup for completing study of #6vs3years of #adjuvant #imatinib 💊i n pts w/ #highrisk #GISTs. Presented at @myESMO @AACR  #virtualplenary over last #2days with #specific discussions from #APAC #discussants as well!…

APODDC reposted

#ESMOVirtualPlenary: And straight after the first abstract session tomorrow (9/5), remain connected to discover more promising results on #GIST. 📢 A randomised study of 6 vs 3 years of adjuvant imatinib in pts w/ localised GIST at high risk of relapse. ow.ly/rKAa50Rza70

myESMO's tweet image. #ESMOVirtualPlenary: And straight after the first abstract session tomorrow (9/5), remain connected to discover more promising results on #GIST. 📢 A randomised study of 6 vs 3 years of adjuvant imatinib in pts w/ localised GIST at high risk of relapse. ow.ly/rKAa50Rza70…

APODDC reposted

Prof Jacky Lam sharing at the @CUHKMedicine Department of Clinical Oncology Academic Meeting on liquid biopsy for early cancer detection #oncology

RashidLui's tweet image. Prof Jacky Lam sharing at the @CUHKMedicine Department of Clinical Oncology Academic Meeting on liquid biopsy for early cancer detection

#oncology

APODDC reposted

Kicked off @ASCO #AsiaPacific #RegionalCouncil meeting in #Kuching #Sarawak 🇲🇾 w/ dedicated council members representing our region and #ASCOStaff. Happy to #vett & #deliver specific initiatives which will benefit #oncology landscape in our region. @DrRoselleDG @DrMLChua

Kudos to the team! Has been part of this amazing team since the beginning in 2019, it’s very encouraging to see where it leads us now. Thankyou @ASCO APAC Regional Council, Pfizer, and Sarawak Gen Hospital team! Great leadership @DrMLChua ! @DrRoselleDG @herbloong @drkiwikate



Loading...

Something went wrong.


Something went wrong.